<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A prospective randomised trial was performed in patients given HLA-identical sibling bone marrow transplants for <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">haematological malignancy</z:e> comparing the combination of cyclosporin and <z:chebi fb="0" ids="44185">methotrexate</z:chebi> (CM) (n = 20) with the combination of cyclosporin, <z:chebi fb="0" ids="44185">methotrexate</z:chebi> and <z:chebi fb="2" ids="8378">prednisolone</z:chebi> (<z:chebi fb="1" ids="17361">CMP</z:chebi>) (n = 21) as prophylaxis for <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host disease</z:e> (GVHD) </plain></SENT>
<SENT sid="1" pm="."><plain>There was no significant differences between the two arms for the incidence of <z:hpo ids='HP_0011009'>acute</z:hpo> GVHD grades I-IV, <z:hpo ids='HP_0011009'>acute</z:hpo> GVHD grades II-IV, <z:hpo ids='HP_0011010'>chronic</z:hpo> GVHD, <z:hpo ids='HP_0006515'>interstitial pneumonitis</z:hpo>, relapse, survival and disease-free survival </plain></SENT>
<SENT sid="2" pm="."><plain>The actuarial incidence of <z:hpo ids='HP_0011009'>acute</z:hpo> GVHD grades II-IV in the <z:chebi fb="1" ids="17361">CMP</z:chebi> group was 10% and in the CM group 15% (ns) </plain></SENT>
<SENT sid="3" pm="."><plain>The incidence of leukaemic relapse in good risk patients was 42% in the <z:chebi fb="1" ids="17361">CMP</z:chebi> group and 40% in the CM group (ns), although the majority of these relapses were cytogenetic relapses only in patients with <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:mpath ids='MPATH_342'>myeloid leukaemia</z:mpath> </plain></SENT>
<SENT sid="4" pm="."><plain>The incidence of <z:hpo ids='HP_0011009'>acute</z:hpo> GVHD grades II-IV in both arms of the current trial was significantly lower than in our previous trial comparing cyclosporin and <z:chebi fb="0" ids="44185">methotrexate</z:chebi> as single agents </plain></SENT>
<SENT sid="5" pm="."><plain>Leukaemic relapse is now the principal cause of treatment failure in this patient population </plain></SENT>
<SENT sid="6" pm="."><plain>We conclude that <z:chebi fb="2" ids="8378">prednisolone</z:chebi> should not be included as part of the prophylactic GVHD regime and that further improvement in therapeutic outcome is dependent upon better control of the underlying <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> </plain></SENT>
</text></document>